Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy

Next Previous
Trial Profile

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berubicin (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CNS Pharmaceuticals

    • Most Recent Events

    • 31 Jan 2024 According to a WPD Pharmaceuticals media release, CNS has successfully enrolled more than 230 patients in this trial, and the Data and Safety Monitoring Board (DSMB) has provided a recommendation following the interim futility analysis to continue the trial without any modification.
    • 11 Sep 2023 Planned End Date changed from 1 Feb 2025 to 1 Jan 2025.
    • 11 Sep 2023 Planned primary completion date changed from 1 Oct 2024 to 1 Sep 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top